Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026
Efficacy and safety of recombinant activated factor VII for spontaneous intracerebral Hemorrhage: a GRADE-assessed meta-analysis of randomized controlled trials using frequentist and Bayesian approaches.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elbahloul Mohammed A, Gamal Aliaa, Ghaly Mayer H, Ragab Maia E, Ainer Mohammed W, Abdelrahman Mohamed Mohamed, Amen Mohamed K, Bawazir Nawaf W, Kotb Abdelrhman Waleed
Аннотация
BACKGROUND: Although spontaneous intracerebral hemorrhage (sICH) accounts for only 10-15% of all strokes, it remains the deadliest subtype. We aimed to evaluate the efficacy and safety of recombinant activated factor VII (rFVIIa) in sICH.
METHODS: We systematically searched four electronic databases through February 28, 2026, for randomized clinical trials (RCTs) comparing rFVIIa with placebo in sICH. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were utilized for dichotomous and continuous outcomes, respectively. The primary efficacy outcomes were good functional outcome (modified Rankin Scale [mRS] 0-2) and poor functional outcome (mRS 4-6) at 90 days.
RESULTS: Seven RCTs, comprising 2,022 patients, were included. Compared with placebo, rFVIIa was not associated with a significant improvement in good functional outcome at 90 days (RR: 1.13, 95% CI: 0.92 to 1.38, p = 0.25) or a significant reduction in intracerebral hemorrhage volume at 24 h (MD: -1.61, 95% CI: -4.42 to 1.19, p = 0.26). Furthermore, rFVIIa was associated with a numerically higher incidence of safety events; however, this difference did not reach statistical significance.
CONCLUSION: In unselected patients with sICH, rFVIIa does not provide a clinically meaningful functional benefit, and the overall evidence supports a recommendation against its routine use.
METHODS: We systematically searched four electronic databases through February 28, 2026, for randomized clinical trials (RCTs) comparing rFVIIa with placebo in sICH. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were utilized for dichotomous and continuous outcomes, respectively. The primary efficacy outcomes were good functional outcome (modified Rankin Scale [mRS] 0-2) and poor functional outcome (mRS 4-6) at 90 days.
RESULTS: Seven RCTs, comprising 2,022 patients, were included. Compared with placebo, rFVIIa was not associated with a significant improvement in good functional outcome at 90 days (RR: 1.13, 95% CI: 0.92 to 1.38, p = 0.25) or a significant reduction in intracerebral hemorrhage volume at 24 h (MD: -1.61, 95% CI: -4.42 to 1.19, p = 0.26). Furthermore, rFVIIa was associated with a numerically higher incidence of safety events; however, this difference did not reach statistical significance.
CONCLUSION: In unselected patients with sICH, rFVIIa does not provide a clinically meaningful functional benefit, and the overall evidence supports a recommendation against its routine use.